Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment 5. Debunking Myths in the US Healthcare System
Top Ten Searches
aldosteronism contrast dialysis vitamin d bicarbonate arf amyloidosis hypocalcemia renal artery husYour Article Summary
See Latest ArticlesRecovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
Medical Oncology, 10/23/09
Karaca H et al. – The authors report a case of paraneoplastic hypercalcemia, resistant to conventional treatment but recovers by sunitinib treatment as the first case in the literature, in a 33–years–old man with metastatic RCC. At the sixth month of follow–up period, in this case, serum calcium level was still in normal ranges. Besides sunitinib is effective in symptom control, it is also helpful in management of paraneoplastic hypercalcemia, a life–threatening entity.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
A Randomized Controlled Study of Weekly and Biweekly Dosing of Epoetin Alfa in CKD Patients With Anemia
Clinical Journal of the American Society of Nephrology, 11/05/09
Incidence of brain metastases in renal cell carcinoma treated with sorafenib
Annals of Oncology, 10/29/09
Article Search
Sponsor